1. Scrip
  2. >>Business

Finance Watch: Pfizer Ventures' Dalton Makes Sense Of Neuroscience Focus Within New $600m VC Fund Commitment

 
• By Mandy Jackson

Venture Capital Edition: Pfizer deprioritized neuroscience as an early R&D focus earlier this year, but will stay involved by spending 25% of the $600m added to its venture fund on neurology investments. Also, China VC investment keeps up fast pace and Alta Partners closes a new $130m health care fund.

Finance Watch

Pfizer Inc.'s commitment of an additional $600m to its corporate venture capital fund includes a plan to spend 25% on neuroscience investments – a curious move considering the company's decision at the start of 2018 to discontinue its own early research and development activities in neuroscience.

Even though Pfizer Ventures was established to invest in small biopharmaceutical companies working in therapeutic areas of interest to Pfizer, the corporate venture fund's Senior Managing Partner Barbara Dalton told Scrip it's not so surprising that the pharma company will invest in early neuroscience pursuits, along

More from Financing

More from Business

Novo Nordisk’s CEO Forced Out After Falling Behind In GLP-1 Battle

 
• By Andrew McConaghie

Company surprises investors with Jørgensen's exit but insists its strategy will not change.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

In Brief: Sanofi Commits $20bn To US R&D And Manufacturing By 2030

 
• By Sushmita Panda

Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.